1. Home
  2. IDAI vs QLGN Comparison

IDAI vs QLGN Comparison

Compare IDAI & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDAI
  • QLGN
  • Stock Information
  • Founded
  • IDAI 2016
  • QLGN 1996
  • Country
  • IDAI United States
  • QLGN United States
  • Employees
  • IDAI N/A
  • QLGN N/A
  • Industry
  • IDAI Computer Software: Prepackaged Software
  • QLGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • IDAI Technology
  • QLGN Health Care
  • Exchange
  • IDAI Nasdaq
  • QLGN Nasdaq
  • Market Cap
  • IDAI 4.9M
  • QLGN 4.7M
  • IPO Year
  • IDAI N/A
  • QLGN N/A
  • Fundamental
  • Price
  • IDAI $3.04
  • QLGN $1.76
  • Analyst Decision
  • IDAI
  • QLGN
  • Analyst Count
  • IDAI 0
  • QLGN 0
  • Target Price
  • IDAI N/A
  • QLGN N/A
  • AVG Volume (30 Days)
  • IDAI 40.7K
  • QLGN 2.6M
  • Earning Date
  • IDAI 08-12-2025
  • QLGN 08-13-2025
  • Dividend Yield
  • IDAI N/A
  • QLGN N/A
  • EPS Growth
  • IDAI N/A
  • QLGN N/A
  • EPS
  • IDAI N/A
  • QLGN N/A
  • Revenue
  • IDAI $3,054,143.00
  • QLGN N/A
  • Revenue This Year
  • IDAI $65.46
  • QLGN N/A
  • Revenue Next Year
  • IDAI $12.00
  • QLGN N/A
  • P/E Ratio
  • IDAI N/A
  • QLGN N/A
  • Revenue Growth
  • IDAI N/A
  • QLGN N/A
  • 52 Week Low
  • IDAI $1.43
  • QLGN $1.76
  • 52 Week High
  • IDAI $18.75
  • QLGN $11.50
  • Technical
  • Relative Strength Index (RSI)
  • IDAI 56.45
  • QLGN 19.98
  • Support Level
  • IDAI $2.60
  • QLGN $2.00
  • Resistance Level
  • IDAI $2.94
  • QLGN $2.98
  • Average True Range (ATR)
  • IDAI 0.20
  • QLGN 0.23
  • MACD
  • IDAI -0.02
  • QLGN -0.11
  • Stochastic Oscillator
  • IDAI 59.58
  • QLGN 0.00

About IDAI T Stamp Inc.

T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.

Share on Social Networks: